Raymond James & Associates’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.38M | Buy |
|
|||||
|
2024
Q2 | $1.13M | Buy |
|
|||||
|
2024
Q1 | $1.11M | Buy |
|
|||||
|
2023
Q4 | $921K | Sell |
|
|||||
|
2023
Q3 | $1.6M | Sell |
|
|||||
|
2023
Q2 | $4.15M | Sell |
|
|||||
|
2023
Q1 | $4.06M | Buy |
|
|||||
|
2022
Q4 | $747K | Buy |
|
|||||
|
2022
Q3 | $958K | Buy |
|
|||||
|
2022
Q2 | $364K | Buy |
|
|||||
|
2022
Q1 | $324K | Sell |
|
|||||
|
2021
Q4 | $323K | Sell |
|
|||||
|
2021
Q3 | $239K | Sell |
|
|||||
|
2021
Q2 | $475K | Sell |
|
|||||
|
2021
Q1 | $666K | Buy |
|
|||||
|
2020
Q4 | $353K | Buy |
|
|||||
|
2020
Q3 | – | Sell |
|
|||||
|
2020
Q2 | $210K | Sell |
|
|||||
|
2020
Q1 | $219K | Buy |
|